Somewhat Positive Press Coverage Somewhat Unlikely to Impact Biogen (BIIB) Stock Price
Press coverage about Biogen (NASDAQ:BIIB) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biogen earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.7452904685397 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- Biogen Inc. Caps Off a Solid 2017, Waits on Aducanumab (finance.yahoo.com)
- Cantor Fitzgerald Analysts Raise Earnings Estimates for Biogen Inc (BIIB) (americanbankingnews.com)
- Jefferies Group Weighs in on Biogen Inc’s Q1 2018 Earnings (BIIB) (americanbankingnews.com)
- Q1 2018 EPS Estimates for Biogen Inc Lifted by Oppenheimer (BIIB) (americanbankingnews.com)
- Brokers Offer Predictions for Biogen Inc’s Q1 2018 Earnings (BIIB) (americanbankingnews.com)
BIIB has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $363.00 price objective (up from $340.00) on shares of Biogen in a report on Friday. Citigroup reissued an “outperform” rating and set a $380.00 price objective (up from $350.00) on shares of Biogen in a report on Tuesday, January 16th. Mizuho set a $400.00 target price on shares of Biogen and gave the company a “buy” rating in a research report on Thursday, January 18th. Jefferies Group restated a “hold” rating on shares of Biogen in a research report on Friday. Finally, Cantor Fitzgerald restated a “hold” rating and set a $279.00 target price on shares of Biogen in a research report on Tuesday, October 24th. Nine research analysts have rated the stock with a hold rating and twenty-three have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $364.72.
Biogen (NASDAQ:BIIB) last posted its earnings results on Thursday, January 25th. The biotechnology company reported $5.26 EPS for the quarter, missing the Zacks’ consensus estimate of $5.44 by ($0.18). The company had revenue of $3.31 billion during the quarter, compared to analysts’ expectations of $3.08 billion. Biogen had a net margin of 20.69% and a return on equity of 38.32%. The company’s quarterly revenue was up 15.1% on a year-over-year basis. During the same period last year, the business earned $5.04 earnings per share. equities research analysts expect that Biogen will post 24.76 EPS for the current year.
In other Biogen news, Director Robert W. Pangia sold 5,832 shares of the firm’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $329.65, for a total transaction of $1,922,518.80. Following the transaction, the director now directly owns 23,539 shares of the company’s stock, valued at approximately $7,759,631.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michel Vounatsos acquired 780 shares of the stock in a transaction on Saturday, December 29th. The shares were acquired at an average cost of $320.55 per share, for a total transaction of $250,029.00. Following the completion of the transaction, the chief executive officer now directly owns 4,879 shares in the company, valued at approximately $1,563,963.45. The disclosure for this purchase can be found here. Insiders purchased a total of 31,560 shares of company stock worth $10,020,858 over the last ninety days. Insiders own 0.25% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Biogen (BIIB) Stock Price” was originally posted by Marea Informative and is the sole property of of Marea Informative. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.mareainformativa.com/2018/01/30/biogen-biib-receiving-somewhat-positive-news-coverage-report-finds-updated-updated-updated.html.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.